Key Takeaways
- Aurora Cannabis’ board recommends shareholders reject Curaleaf’s revised offer, indicating it undervalues the company.
- Curaleaf’s latest proposal offers $1.00 in cash plus 0.4013 shares, valued at about $5.00 per share, an increase from the original bid.
- Aurora holds valuable EU-GMP certified facilities crucial for accessing European markets, adding to its appeal to potential buyers.
- The negotiation between big players illustrates the widening gap between large and small cannabis operators in the industry.
- Curaleaf’s offer remains open until December 4, as Aurora plans to evaluate its options and provide further guidance.
Here we go again. A little over a month after our earlier coverage of Aurora Cannabis rejecting Curaleaf’s first hostile bid, Aurora’s board is back with the same message, this time about a sweetened offer. According to Aurora’s October 14th press release, the board unanimously recommends shareholders reject Curaleaf’s revised bid and take no action.
We run a small operation in comparison to these two. We know what it’s like to count every dollar twice before spending it. So when two multinational cannabis companies spend months publicly arguing over hundreds of millions of dollars, it’s worth asking what that fight actually means for the rest of us, and for patients who depend on steady access to medicine.
What Did Aurora’s Board Actually Say on October 14?
Aurora’s special committee of independent directors got an updated fairness opinion from its financial advisor. That opinion said the revised offer is still inadequate from a financial standpoint. Based on that, and on the committee’s unanimous recommendation, the full board told shareholders to reject the bid.
Aurora CEO and Executive Chairman Miguel said: “Curaleaf’s revised offer still does not reflect the value of the company Aurora shareholders own today. Aurora is debt-free with a strong cash position,” he said in the October 14 release. Martin also noted that Curaleaf’s offer runs until December 4, 2026, adding that shareholders “gain nothing by tendering now.”
Aurora’s board listed several objections. The cash portion is partly funded by Aurora’s own balance sheet. The increased consideration is mostly more Curaleaf stock, which means Aurora shareholders would still carry the risk of Curaleaf’s share price falling. And the board argues Curaleaf hasn’t adequately supported its claimed cost synergies, meaning most of that upside would land with Curaleaf’s existing shareholders, not Aurora’s.
How Much Bigger Is Curaleaf’s Revised Offer?
The numbers moved, but not into billion-dollar territory for the deal itself. The revised offer consists of US$1.00 in cash plus 0.4013 of a Curaleaf share per Aurora share, which Curaleaf values at about US$5.00 based on its October 2 closing price. That’s up from the original offer of US$0.75 cash plus 0.3463 shares, worth around US$4.00 at announcement, according to Curaleaf’s August 18th release.
StratCann reported the cash component rose 33%, and the maximum payout cap increased from US$5.00 to US$6.00 per share. Curaleaf describes the increased total value as a 25% bump and an 86% premium over Aurora’s unaffected share price, though that’s Curaleaf’s own framing, not an independently audited figure.
Why Does Everyone Want Aurora’s European Assets?
This is where the story gets interesting if you’re not a shareholder of either company. Aurora operates EU-GMP certified facilities in Germany and Canada, including Leuna in Germany and several Canadian sites. Aurora is one of only three companies holding a licensed production facility in Germany. That’s not a small detail. EU-GMP certification, import licensing, and pharmacy relationships take years to build and involve regulators most companies would rather avoid dealing with twice.
Aurora’s Q1 fiscal 2027 results, covering the three months ended June 30, 2026, showed international medical net revenue of $43.3 million, up 17% year over year, driven largely by higher sales in Germany. Canadian medical revenue, by contrast, fell 25% over the same period. That split tells you where the real growth, and the real appeal to an acquirer, is coming from.
Curaleaf already moved on this thesis once. In 2024, it acquired Northern Green Canada specifically for its EU-GMP facility, per StratCann. Buying Aurora would hand Curaleaf a much bigger version of the same prize.
What Does This Mean for Smaller Cannabis Operators?
Here’s our honest take. We don’t have a financial advisor on retainer or a special committee of independent directors. What we have is a product to get on shelves, compliance paperwork that never seems to shrink, and customers who notice when prices move. When two large operators spend months negotiating in public over access to European infrastructure, it’s a reminder of how far apart the top and bottom of this industry have grown.
That gap matters because consolidation at the top can ripple down. Fewer independent suppliers controlling EU-GMP capacity could mean less flexibility for smaller brands trying to get into European markets, or it could open licensing and partnership doors if either company needs distribution help post-deal. We don’t know which way it breaks yet. What we do know is that watching this fight play out gives smaller operators a preview of where capital and attention are headed next.
What Happens Next?
Curaleaf’s revised offer stays open until December 4th. Aurora’s board says it will provide a further recommendation once it has finished evaluating its alternatives. Until then, nothing is settled, and shareholders have been told explicitly to hold tight rather than tender their shares.
We’ll keep tracking this one, not because we have a stake in who wins, but because the outcome will say a lot about who gets to control the pipeline connecting European patients to their medicine, and what room that leaves for the rest of us.
Frequently Asked Questions
Yes. On October 14, 2026, Aurora’s board unanimously recommended that shareholders reject Curaleaf’s revised hostile bid, citing an updated fairness opinion that found the offer financially inadequate.
Curaleaf’s revised offer consists of US$1.00 in cash plus 0.4013 of a Curaleaf share per Aurora share, valued at approximately US$5.00 based on Curaleaf’s October 2, 2026 closing price, up from the original US$4.00 offer.
The revised offer remains open until 5:00 p.m. on December 4, 2026. Aurora’s board has advised shareholders to take no action before that date.
Aurora holds EU-GMP certified manufacturing facilities in Germany and Canada, making it one of only three companies with licensed production in Germany. That infrastructure, along with import licensing and pharmacy access, is difficult and time-consuming to replicate, which is why it’s central to Curaleaf’s interest in acquiring Aurora.
